Related Experiment Video

Updated: Mar 2, 2026

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

3.0K

Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives

Salvatore Giovanni Vitale1, Antonio Simone Laganà2, Stella Capriglione3

  • 1Unit of Gynecology and Obstetrics, Department of Human Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, 98125 Messina, Italy. vitalesalvatore@hotmail.com.

International Journal of Molecular Sciences
|May 23, 2017
PubMed

Insights

Uterine carcinosarcomas (CS) have a poor prognosis. Novel therapies targeting epithelial cell adhesion molecule-1 and Human Epidermal Growth Factor Receptor 2 (HER2) show promise for treating this rare gynecologic cancer.

Area of Science:

  • Gynecologic Oncology
  • Translational Cancer Research

Background:

  • Uterine carcinosarcomas (CS) are rare, aggressive gynecologic cancers, comprising 2-5% of uterine malignancies.
  • Current treatments (surgery, chemotherapy) yield a poor 5-year survival rate (30 ± 9%) with high recurrence rates (50-80%).

Purpose of the Study:

  • To systematically review emerging therapeutic strategies for uterine CS.
  • To identify novel treatment targets and assess their potential impact on patient outcomes.

Main Methods:

  • Systematic literature review using keywords: "uterine carcinosarcoma", "uterine Malignant Mixed Müllerian Tumors", "target therapies", "angiogenesis therapy", "cancer stem cell therapy", "prognostic biomarker", and "novel antibody-drug".

Main Results:

  • Differential expression of epithelial cell adhesion molecule-1 on metastatic/chemotherapy-resistant CS cells suggests it as a potential therapeutic target.
  • Human Epidermal Growth Factor Receptor 2 (HER2) also presents a targetable pathway for novel therapies.

Conclusions:

  • Targeted therapies focusing on epithelial cell adhesion molecule-1 and HER2 offer new avenues for uterine CS treatment.
  • Further research is crucial to validate the efficacy of these novel therapies and their impact on survival and long-term outcomes.
Keywords:
carcinosarcomasepigeneticsgeneticsimmunotherapyuterine cancer

More Related Videos

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.7K
Stereotactic Radiosurgery for Gynecologic Cancer10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K